HomeStock SectorsBioTechWhy Are Biotech Stocks...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.

What Happened?

The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.

OI, also known as brittle bone disease, is a group of genetic disorders that make bones abnormally fragile and prone to fractures.

Also Read: Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

William Blair noted that the update implies the second interim analysis did not meet the minimal p-value threshold of p<0.01 to end the study early.

The Data Monitoring Committee (DMC) met and informed the company that UX143 demonstrates an acceptable safety profile, and the company should continue the study to the final analysis.

“While we had hoped to be able to stop the study early, we look forward to having results from both Orbit and Cosmic around the end of this year,” said Emil Kakkis, chief executive officer and president of Ultragenyx.

Consistent with the statistical analysis plan, data from the Cosmic study were not analyzed at this interim time point. The study is going well, and safety in this younger patient population is consistent with the safety profile of the other studies.

Patients will continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies. The final analyses will be conducted after patients have been on therapy for at least 18 months.

The threshold for the Phase 3 Orbit final analysis is p<0.04, and for the Phase 3 Cosmic final analysis is p<0.05.

Analyst’s Take

William Blair acknowledged the disappointment that the Orbit study didn’t achieve statistical significance at the second interim analysis. However, they believe the market’s reaction is severely overdone. They anticipate a high likelihood of a positive outcome from the final analysis in the fourth quarter, citing the longer follow-up duration and a lower statistical significance threshold.

Analyst Sami Corwin from William Blair reiterated, “We continue to believe that the Phase II Orbit data support setrusumab as a clinically active molecule in OI, and we do not think this update impacts the top-line analyses’ probability of success.”

Price Action: RARE stock is trading lower by 26.2% to $30.60, and MREO stock is down 34.7% at $1.919 at last check Thursday.

Read Next:

Photo via Shutterstock

Most Popular

More from Author

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos...

Read Now

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1...

Greece's 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.Fast forward 15 years, and the picture couldn't be more different.The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

3 Things to Watch This Week: Trade-War Worries, Earnings, and Record Highs

After the long holiday weekend, we’re back to a full week of trading. Here are a few things we’re watching for this week. First, trade-war headlines. The Trump Administration’s original deadline was July 9th, and while that date is still in focus for investors, it now appears that many...

The Energy Report: Peak Oil Demand

Just breaking… is discussing pausing their output production hikes from October, saying that we would not ever consume as much oil as we did in the past. As predicted the “Peak Demand” oil theory has been dis-proven again. The United Arab Emirates oil minister Suhail Al Mazroui said that...

Why Is Pelthos Therapeutics Stock Trading Higher Thursday – Pelthos Therapeutics (AMEX:PTHS)

Pelthos Therapeutics Inc. PTHS on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.Zelsuvmi received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is...